Gamma Hydroxybutyric Acid (GHB) for the Treatment of Alcohol Dependence: A Review

Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter γ-aminobutyric acid. Clinical trials have demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of environmental research and public health Vol. 6; no. 6; pp. 1917 - 1929
Main Authors Caputo, Fabio, Vignoli, Teo, Maremmani, Icro, Bernardi, Mauro, Zoli, Giorgio
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.06.2009
Molecular Diversity Preservation International (MDPI)
Subjects
Addictions
Alcohol use
Alcoholism - drug therapy
Fatty acids
Humans
Hydroxybutyrates - therapeutic use
Motivation
Randomized Controlled Trials as Topic
Review
Substance Withdrawal Syndrome - drug therapy
alcohol withdrawal syndrome
gamma-hydroxybutyric acid
anti-craving drug
Online AccessGet full text
ISSN1660-4601
1661-7827
1660-4601
1661-7827
DOI10.3390/ijerph6061917

Cover

Abstract Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter γ-aminobutyric acid. Clinical trials have demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10-15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction.
AbstractList Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter gamma-aminobutyric acid. Clinical trials have demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10-15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction.Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter gamma-aminobutyric acid. Clinical trials have demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10-15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction.
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter γ-aminobutyric acid. Clinical trials have demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10-15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction. [PUBLICATION ABSTRACT]
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter gamma-aminobutyric acid. Clinical trials have demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10-15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction.
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter γ-aminobutyric acid. Clinical trials have demonstrated that 50–100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10–15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction.
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter I3-aminobutyric acid. Clinical trials have demonstrated that 50a100 mg/kg of GHB fractioned into three or six daily doses is able to suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from alcohol. These studies have also shown that GHB craving episodes are a very limited phenomenon (about 10a15%). Thus, physicians with access should consider the clinical efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction.
Author Caputo, Fabio
Zoli, Giorgio
Vignoli, Teo
Maremmani, Icro
Bernardi, Mauro
AuthorAffiliation 1 Department of Internal Medicine, SS Annunziata Hospital, Cento (Ferrara), Italy; E-Mail: g.zoli@ausl.fe.it
3 Vincent P. Dole Dual Diagnosis Unit, Santa Chiara University Hospital, Department of Psychiatry, NPB, University of Pisa, Italy; E-Mail: info@aucns.org
2 “G. Fontana” Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna, Italy; E-Mails: tvignoli@yahoo.com (T.V.); mauro.bernardi@unibo.it (M.B.)
AuthorAffiliation_xml – name: 3 Vincent P. Dole Dual Diagnosis Unit, Santa Chiara University Hospital, Department of Psychiatry, NPB, University of Pisa, Italy; E-Mail: info@aucns.org
– name: 1 Department of Internal Medicine, SS Annunziata Hospital, Cento (Ferrara), Italy; E-Mail: g.zoli@ausl.fe.it
– name: 2 “G. Fontana” Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna, Italy; E-Mails: tvignoli@yahoo.com (T.V.); mauro.bernardi@unibo.it (M.B.)
Author_xml – sequence: 1
  givenname: Fabio
  orcidid: 0000-0002-8953-8338
  surname: Caputo
  fullname: Caputo, Fabio
– sequence: 2
  givenname: Teo
  surname: Vignoli
  fullname: Vignoli, Teo
– sequence: 3
  givenname: Icro
  surname: Maremmani
  fullname: Maremmani, Icro
– sequence: 4
  givenname: Mauro
  orcidid: 0000-0002-1308-5440
  surname: Bernardi
  fullname: Bernardi, Mauro
– sequence: 5
  givenname: Giorgio
  surname: Zoli
  fullname: Zoli, Giorgio
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19578468$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1PGzEQxa0K1EDaY6-VxQHBYcFfsb09IAVKE6RIVav0bHm9s8TR7jr17gL577sRKUoQEqcZaX7z9GbeMTqoQw0IfaHkgvOUXPolxNVCEklTqj6gIyolSYQk9GCnH6DjplkSwrWQ6Uc0oOlI9a0-Qr8mtqosnq7zGJ7WWdeuo3d47HyOzybT63NchIjbBeB5BNtWULc4FHhcurAIJf4OK6hzqB18w2P8Gx48PH5Ch4UtG_i8rUP058ft_GaazH5O7m7Gs8QJwdskc8CFtoXTWUYEUaKgolACHNejLFUy1YxZlVtwlktL05RzlXPpwEpbUDXiQ3T1rLvqsgpy11uLtjSr6Csb1yZYb_YntV-Y-_BgmCIjxjYCp1uBGP520LSm8o2DsrQ1hK4xUgmhpKbvgoxorWn_3SE6eQUuQxfr_guGMcUlJUz30Ndd3y-G_2fSA_wZcDE0TYTCON_a1ofNGb40lJhN8mYv-X4rebX1Ivwm_w-0J7A_
CitedBy_id crossref_primary_10_1124_jpet_110_170670
crossref_primary_10_1016_j_genhosppsych_2012_06_016
crossref_primary_10_1016_j_neubiorev_2012_02_002
crossref_primary_10_37319_iqnjm_1_2_3
crossref_primary_10_1016_j_euroneuro_2010_12_005
crossref_primary_10_1111_1750_3841_12234
crossref_primary_10_1093_jas_skad155
crossref_primary_10_1021_acschemneuro_9b00336
crossref_primary_10_1111_jpi_12417
crossref_primary_10_1016_j_forsciint_2019_109958
crossref_primary_10_1111_1471_0307_12261
crossref_primary_10_1039_C2AY26009C
crossref_primary_10_3389_fnbeh_2022_893835
crossref_primary_10_1002_hup_2491
crossref_primary_10_1016_j_microc_2022_107483
crossref_primary_10_1021_jm1006325
crossref_primary_10_1007_s10068_013_0057_1
crossref_primary_10_1016_j_toxac_2019_03_137
crossref_primary_10_1007_s12501_014_0023_5
crossref_primary_10_1002_dta_292
crossref_primary_10_4303_jdar_235801
crossref_primary_10_1016_S1734_1140_11_70700_9
crossref_primary_10_1007_s00253_014_6191_8
crossref_primary_10_7740_kjcs_2012_57_2_144
crossref_primary_10_1111_1556_4029_12201
crossref_primary_10_1007_s40261_013_0158_x
crossref_primary_10_1016_j_foodchem_2011_04_090
crossref_primary_10_1016_j_neuroscience_2014_07_056
crossref_primary_10_1097_WNR_0000000000000586
crossref_primary_10_3390_brainsci13081206
crossref_primary_10_1111_j_1471_4159_2010_06901_x
crossref_primary_10_3390_pr10010037
crossref_primary_10_1007_s00216_015_9051_1
crossref_primary_10_1016_j_forsciint_2012_04_009
crossref_primary_10_1177_0269881111408463
crossref_primary_10_1093_alcalc_agad090
crossref_primary_10_1016_j_neuroscience_2013_06_011
crossref_primary_10_1097_ADT_0000000000000055
crossref_primary_10_1002_adsc_201300073
crossref_primary_10_1002_dta_1498
crossref_primary_10_3390_brainsci14030294
crossref_primary_10_1007_s00216_010_4183_9
crossref_primary_10_3109_15563650_2012_702218
crossref_primary_10_1007_s11739_024_03761_x
Cites_doi 10.1016/S0741-8329(99)00091-9
10.1016/S0740-5472(96)00157-2
10.1111/j.1365-2125.1992.tb04129.x
10.1159/000084161
10.1056/NEJMra044047
10.1093/oxfordjournals.alcalc.a008216
10.1096/fj.02-0846fje
10.1080/00952990701315046
10.1016/0014-2999(94)00687-3
10.1080/02791072.2006.10399846
10.1093/oxfordjournals.alcalc.a008160
10.1007/BF00265954
10.1016/j.pharmthera.2004.12.004
10.1097/00003643-199809000-00009
10.1016/S0140-6736(09)60848-5
10.1016/S0140-6736(07)60237-2
10.1111/j.1365-2044.1968.tb00119.x
10.1016/S0140-6736(89)90842-8
10.1097/01.ALC.0000153542.10188.B0
10.1002/cne.21072
10.1016/j.pharmthera.2008.10.003
10.1016/0028-3908(93)90163-W
10.1097/01.jcp.0000237944.57893.28
10.1080/02791072.2001.10400478
10.1096/fj.06-6509com
10.1007/s002280050113
10.1016/S0014-2999(02)01502-9
10.1016/S0741-8329(99)00085-3
10.1097/01.wnf.0000159954.49393.76
10.1097/00003643-199711000-00006
10.1093/sleep/9.1.285
10.1016/j.pnpbp.2007.09.021
10.1176/appi.ajp.162.8.1403
10.1093/alcalc/37.1.67
10.1016/0024-3205(82)90624-5
10.1016/S0376-8716(98)00094-5
10.1016/S0376-8716(00)00191-5
10.1111/j.1530-0277.1992.tb00658.x
10.1016/j.phrs.2008.03.001
10.1007/s11065-008-9080-z
10.1016/j.euroneuro.2007.04.008
10.1038/sj.mp.4001507
10.1093/alcalc/34.2.197
10.1016/S0014-2999(01)01334-6
10.1097/01.jcp.0000280314.04237.a7
10.1002/syn.20355
10.1517/13543780902905855
10.1016/S0140-6736(05)66737-2
10.1016/S0140-6736(05)67371-0
10.1016/S0376-8716(02)00340-X
10.1111/j.1472-8206.2006.00459.x
10.1093/alcalc/33.5.465
10.1016/0006-2952(84)90629-4
10.1080/15563650701263633
10.1038/2001207a0
10.1016/S0741-8329(99)00084-1
10.1177/0269881108094620
10.1111/j.1471-4159.2004.02525.x
10.1523/JNEUROSCI.23-08-03498.2003
10.1016/j.drugalcdep.2004.09.003
ContentType Journal Article
Copyright Copyright Molecular Diversity Preservation International Jun 2009
2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 2009
Copyright_xml – notice: Copyright Molecular Diversity Preservation International Jun 2009
– notice: 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 2009
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7TK
7X8
5PM
DOI 10.3390/ijerph6061917
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Neurosciences Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database
MEDLINE

CrossRef
Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1660-4601
1661-7827
EndPage 1929
ExternalDocumentID PMC2705225
1855088081
19578468
10_3390_ijerph6061917
Genre Journal Article
Review
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
7XC
88E
8C1
8FE
8FG
8FH
8FI
8FJ
8R4
8R5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABGAM
ABUWG
ACGFO
ACGOD
ACIWK
ADBBV
ADRAZ
AENEX
AFKRA
AFRAH
AFZYC
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
EMB
EMOBN
F5P
FYUFA
GX1
HH5
HMCUK
HYE
IPNFZ
KQ8
L6V
M1P
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
Q2X
RIG
RNS
RPM
SV3
TR2
UKHRP
XSB
CGR
CUY
CVF
EBD
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7TK
ESTFP
PUEGO
7X8
5PM
ID FETCH-LOGICAL-c443t-bce348afc8bb04074f14f74ec385b9769822a7daeca36a199337d36cea6af1753
IEDL.DBID M48
ISSN 1660-4601
1661-7827
IngestDate Thu Aug 21 17:17:19 EDT 2025
Mon Sep 08 05:10:48 EDT 2025
Fri Sep 05 14:49:40 EDT 2025
Fri Jul 25 05:58:22 EDT 2025
Thu Apr 03 06:59:48 EDT 2025
Tue Jul 01 01:15:33 EDT 2025
Thu Apr 24 23:03:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords alcohol withdrawal syndrome
gamma-hydroxybutyric acid
anti-craving drug
Language English
License https://creativecommons.org/licenses/by/3.0
This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c443t-bce348afc8bb04074f14f74ec385b9769822a7daeca36a199337d36cea6af1753
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
ORCID 0000-0002-1308-5440
0000-0002-8953-8338
OpenAccessLink https://www.proquest.com/docview/227361028?pq-origsite=%requestingapplication%&accountid=15518
PMID 19578468
PQID 227361028
PQPubID 54923
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2705225
proquest_miscellaneous_67447681
proquest_miscellaneous_20888100
proquest_journals_227361028
pubmed_primary_19578468
crossref_citationtrail_10_3390_ijerph6061917
crossref_primary_10_3390_ijerph6061917
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-06-01
PublicationDateYYYYMMDD 2009-06-01
PublicationDate_xml – month: 06
  year: 2009
  text: 2009-06-01
  day: 01
PublicationDecade 2000
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of environmental research and public health
PublicationTitleAlternate Int J Environ Res Public Health
PublicationYear 2009
Publisher MDPI AG
Molecular Diversity Preservation International (MDPI)
Publisher_xml – name: MDPI AG
– name: Molecular Diversity Preservation International (MDPI)
References Carai (ref_13) 2001; 428
Davies (ref_25) 2003; 28
Nimmerrichter (ref_33) 2002; 37
Shi (ref_62) 2007; 28
Caputo (ref_48) 2005; 28
Colombo (ref_36) 1995; 273
Mamelak (ref_15) 1986; 9
Carter (ref_1) 2009; 121
Tunnicliff (ref_19) 2002; 3
ref_54
Xi (ref_59) 2003; 23
ref_52
Johnson (ref_63) 2005; 29
Addolorato (ref_41) 1998; 53
Addolorato (ref_53) 2000; 20
Campanini (ref_20) 2000; 20
Addolorato (ref_40) 1996; 31
Agabio (ref_35) 1998; 33
Broughton (ref_17) 1980; 7
Snead (ref_21) 2005; 352
Kalivas (ref_55) 2005; 162
Ricaurte (ref_67) 2005; 365
Snead (ref_27) 1993; 32
Tambour (ref_64) 2007; 21
Snead (ref_6) 1984; 33
Ferrara (ref_23) 1992; 34
Anderson (ref_57) 2005; 106
Volkow (ref_58) 2004; 9
Benavides (ref_5) 1982; 30
Nie (ref_26) 1994; 271
Nicholson (ref_66) 2000; 63
Nava (ref_47) 2006; 38
Gallimberti (ref_39) 1992; 16
Rosen (ref_56) 1997; 14
Kleinschmidt (ref_11) 1998; 15
Addolorato (ref_51) 2005; 51
Gianoulakis (ref_2) 1996; 31
Caputo (ref_45) 2007; 17
Biggio (ref_38) 1992; 47
Dauvilliers (ref_18) 2007; 369
Ferrara (ref_24) 1996; 50
Leggio (ref_29) 2008; 32
Malcolm (ref_28) 2003; 64
Gallimberti (ref_30) 1989; 2
Thai (ref_43) 2006; 26
Caputo (ref_69) 2005; 366
Caputo (ref_71) 2009; 373
Carai (ref_16) 2002; 441
Caputo (ref_44) 2003; 70
Aldrete (ref_9) 1968; 23
Addolorato (ref_65) 2005; 77
Laborit (ref_4) 1960; 68
Kemmel (ref_12) 2006; 498
Bessmann (ref_3) 1963; 200
Mamelak (ref_14) 1977; 12
Korninger (ref_34) 2003; 3
Gessa (ref_37) 2000; 20
Maremmani (ref_42) 2001; 33
Jayaram (ref_60) 2004; 90
Kleinschmidt (ref_10) 1997; 14
Nava (ref_32) 2007; 33
Palatini (ref_22) 1993; 45
Martin (ref_61) 2007; 61
Caputo (ref_46) 2007; 27
Addolorato (ref_31) 1999; 23
Stella (ref_49) 2008; 57
Andriamampandry (ref_8) 2007; 21
Addolorato (ref_70) 2009; 18
Verheul (ref_50) 1999; 34
Andriamampandry (ref_7) 2003; 17
Knudsen (ref_68) 2008; 46
References_xml – volume: 3
  start-page: 278
  year: 2002
  ident: ref_19
  article-title: Gamma-hydroxybutyrate (orphan medical)
  publication-title: Curr. Opin. Investig. Drugs
– volume: 20
  start-page: 271
  year: 2000
  ident: ref_37
  article-title: Mechanism of the anti-alcohol effect of gamma-hydroxybutyric acid
  publication-title: Alcohol
  doi: 10.1016/S0741-8329(99)00091-9
– volume: 14
  start-page: 149
  year: 1997
  ident: ref_56
  article-title: Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients
  publication-title: J. Subst. Abuse Treat
  doi: 10.1016/S0740-5472(96)00157-2
– volume: 34
  start-page: 231
  year: 1992
  ident: ref_23
  article-title: Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses
  publication-title: Br. J. Clin. Pharmacol
  doi: 10.1111/j.1365-2125.1992.tb04129.x
– volume: 47
  start-page: 281
  year: 1992
  ident: ref_38
  article-title: Suppression of voluntary ethanol intake in rats and alcoholics by gamma-hydroxybutyric acid: a non-GABAergic mechanism
  publication-title: Adv. Biochem. Psychopharmacol
– volume: 51
  start-page: 59
  year: 2005
  ident: ref_51
  article-title: How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review
  publication-title: Neuropsychobiology
  doi: 10.1159/000084161
– volume: 352
  start-page: 2721
  year: 2005
  ident: ref_21
  article-title: Gamma-hydroxybutyric acid
  publication-title: N. Engl. J. Med
  doi: 10.1056/NEJMra044047
– volume: 31
  start-page: 33
  year: 1996
  ident: ref_2
  article-title: Implication of endogenous opioids and dopamine in alcoholism: human and basic science studies
  publication-title: Alcohol Alcoholism
  doi: 10.1093/oxfordjournals.alcalc.a008216
– volume: 17
  start-page: 1691
  year: 2003
  ident: ref_7
  article-title: Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB)
  publication-title: FASEB J
  doi: 10.1096/fj.02-0846fje
– volume: 33
  start-page: 379
  year: 2007
  ident: ref_32
  article-title: Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam
  publication-title: Amer. J. Drug Alcohol Abuse
  doi: 10.1080/00952990701315046
– volume: 273
  start-page: 235
  year: 1995
  ident: ref_36
  article-title: Cross tolerance to ethanol and gamma-hydroxybutyric acid
  publication-title: Eur. J. Pharmacol
  doi: 10.1016/0014-2999(94)00687-3
– volume: 28
  start-page: 263
  year: 2003
  ident: ref_25
  article-title: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system
  publication-title: J. Psychiatry Neurosci
– volume: 38
  start-page: 211
  year: 2006
  ident: ref_47
  article-title: Comparing treatments of alcoholism on craving and bio-chemical measures of alcohol consumptions
  publication-title: J. Psychoactive Drug
  doi: 10.1080/02791072.2006.10399846
– volume: 31
  start-page: 341
  year: 1996
  ident: ref_40
  article-title: An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group
  publication-title: Alcohol Alcoholism
  doi: 10.1093/oxfordjournals.alcalc.a008160
– volume: 23
  start-page: 1596
  year: 1999
  ident: ref_31
  article-title: Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine
  publication-title: Alcohol Clin. Exp. Res
– volume: 45
  start-page: 353
  year: 1993
  ident: ref_22
  article-title: Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers
  publication-title: Eur. J. Clin. Pharmacol
  doi: 10.1007/BF00265954
– volume: 106
  start-page: 389
  year: 2005
  ident: ref_57
  article-title: Cocaine-induced alterations in dopamine receptor signalling: implications for reinforcement and reinstatement
  publication-title: Pharmacol. Ther
  doi: 10.1016/j.pharmthera.2004.12.004
– volume: 15
  start-page: 559
  year: 1998
  ident: ref_11
  article-title: Total intravenous anaesthesia with gamma-hydroxybutyrate (GHB) and sufentanil in patients undergoing coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function
  publication-title: Eur. J. Anaesthesiol
  doi: 10.1097/00003643-199809000-00009
– volume: 7
  start-page: 23
  year: 1980
  ident: ref_17
  article-title: Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy
  publication-title: Can. J. Neurol. Sci
– volume: 64
  start-page: 36
  year: 2003
  ident: ref_28
  article-title: GABA systems, benzodiazepines, and substance dependence
  publication-title: J. Clin. Psychiatry
– volume: 373
  start-page: 1519
  year: 2009
  ident: ref_71
  article-title: Treatment of alcohol use disorders
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60848-5
– volume: 369
  start-page: 499
  year: 2007
  ident: ref_18
  article-title: Narcolepsy with cataplexy
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60237-2
– volume: 23
  start-page: 558
  year: 1968
  ident: ref_9
  article-title: 4-Hydroxybutyrate anaesthesia for cardiovascular surgery. A comparison with halothane
  publication-title: Anaesthesia
  doi: 10.1111/j.1365-2044.1968.tb00119.x
– volume: 2
  start-page: 787
  year: 1989
  ident: ref_30
  article-title: Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome
  publication-title: Lancet
  doi: 10.1016/S0140-6736(89)90842-8
– volume: 29
  start-page: 248
  year: 2005
  ident: ref_63
  article-title: Safety and efficacy of GABAergic medications for treating alcoholism
  publication-title: Alcohol. Clin. Exp. Res
  doi: 10.1097/01.ALC.0000153542.10188.B0
– volume: 498
  start-page: 508
  year: 2006
  ident: ref_12
  article-title: Immunohistochemical localization of a GHB receptor-like protein isolated from rat brain
  publication-title: J. Comp. Neurol
  doi: 10.1002/cne.21072
– volume: 121
  start-page: 100
  year: 2009
  ident: ref_1
  article-title: Behavioral analyses of GHB: receptor mechanisms
  publication-title: Pharmacol. Ther
  doi: 10.1016/j.pharmthera.2008.10.003
– volume: 32
  start-page: 401
  year: 1993
  ident: ref_27
  article-title: GABAA receptor function in the g-hydroxybutyrate model of generalized absence seizures
  publication-title: Neuropharmacology
  doi: 10.1016/0028-3908(93)90163-W
– volume: 26
  start-page: 524
  year: 2006
  ident: ref_43
  article-title: Gamma-hydroxybutyrate and ethanol effects and interactions in humans
  publication-title: J. Clin. Psychopharmacol
  doi: 10.1097/01.jcp.0000237944.57893.28
– volume: 33
  start-page: 135
  year: 2001
  ident: ref_42
  article-title: Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics
  publication-title: J. Psychoactive Drug
  doi: 10.1080/02791072.2001.10400478
– volume: 21
  start-page: 885
  year: 2007
  ident: ref_8
  article-title: Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain
  publication-title: FASEB. J
  doi: 10.1096/fj.06-6509com
– volume: 50
  start-page: 305
  year: 1996
  ident: ref_24
  article-title: Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid
  publication-title: Eur. J. Clin. Pharmacol
  doi: 10.1007/s002280050113
– volume: 441
  start-page: 157
  year: 2002
  ident: ref_16
  article-title: Central effects of 1, 4-butanediol are mediated by GABAB receptors via its conversion into γ-hydroxybutyric acid
  publication-title: Eur. J. Pharmacol
  doi: 10.1016/S0014-2999(02)01502-9
– volume: 20
  start-page: 223
  year: 2000
  ident: ref_20
  article-title: Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependents patients
  publication-title: Alcohol
  doi: 10.1016/S0741-8329(99)00085-3
– volume: 28
  start-page: 87
  year: 2005
  ident: ref_48
  article-title: Alcoholism Treatment Study Group. Suppression of craving for γ-hydroxybutyric acid by naltrexone administration: three case reports
  publication-title: Clin. Neuropharmacol
  doi: 10.1097/01.wnf.0000159954.49393.76
– volume: 68
  start-page: 1867
  year: 1960
  ident: ref_4
  article-title: Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate
  publication-title: Presse Medicale
– volume: 14
  start-page: 590
  year: 1997
  ident: ref_10
  article-title: Total intravenous anaesthesia using propofol, gamma-hydroxybutyrate or midazolam in combination with sufentanil for patients undergoing coronary artery bypass surgery
  publication-title: Eur. J. Anaesthesiol
  doi: 10.1097/00003643-199711000-00006
– volume: 9
  start-page: 285
  year: 1986
  ident: ref_15
  article-title: Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings
  publication-title: Sleep
  doi: 10.1093/sleep/9.1.285
– volume: 32
  start-page: 1106
  year: 2008
  ident: ref_29
  article-title: New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications
  publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry
  doi: 10.1016/j.pnpbp.2007.09.021
– volume: 162
  start-page: 1403
  year: 2005
  ident: ref_55
  article-title: The neural basis of addiction: A pathology of motivation and choice
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.162.8.1403
– volume: 37
  start-page: 67
  year: 2002
  ident: ref_33
  article-title: Double blind controlled trial of γ-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal
  publication-title: Alcohol Alcoholism
  doi: 10.1093/alcalc/37.1.67
– volume: 30
  start-page: 953
  year: 1982
  ident: ref_5
  article-title: High affinity binding sites for gamma-hydroxybutyric acid in rat brain
  publication-title: Life Sci
  doi: 10.1016/0024-3205(82)90624-5
– volume: 53
  start-page: 7
  year: 1998
  ident: ref_41
  article-title: Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients
  publication-title: Drug Alcohol Depend
  doi: 10.1016/S0376-8716(98)00094-5
– volume: 63
  start-page: 1
  year: 2000
  ident: ref_66
  article-title: GHB: a new and novel drug of abuse
  publication-title: Drug Alcohol Depend
  doi: 10.1016/S0376-8716(00)00191-5
– volume: 16
  start-page: 673
  year: 1992
  ident: ref_39
  article-title: Gamma-hydroxybutyric acid in the treatment of alcohol dependance: a double-blind study
  publication-title: Alcohol. Clin. Exp. Res
  doi: 10.1111/j.1530-0277.1992.tb00658.x
– volume: 12
  start-page: 273
  year: 1977
  ident: ref_14
  article-title: The effects of γ-hydroxybutyrate on sleep
  publication-title: Biol. Psychiatry
– volume: 57
  start-page: 312
  year: 2008
  ident: ref_49
  article-title: An open randomized study of the treatment of escitalopram alone and combined with γ-hydroxybutyric acidand naltrexone in alcoholic patients
  publication-title: Pharmacol. Res
  doi: 10.1016/j.phrs.2008.03.001
– ident: ref_52
  doi: 10.1007/s11065-008-9080-z
– volume: 17
  start-page: 781
  year: 2007
  ident: ref_45
  article-title: Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study
  publication-title: Eur. Neuropsychopharmacol
  doi: 10.1016/j.euroneuro.2007.04.008
– volume: 9
  start-page: 557
  year: 2004
  ident: ref_58
  article-title: Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
  publication-title: Mol. Psychiatry
  doi: 10.1038/sj.mp.4001507
– volume: 271
  start-page: 1566
  year: 1994
  ident: ref_26
  article-title: Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms
  publication-title: J. Pharmacol. Exp. Ther
– volume: 34
  start-page: 197
  year: 1999
  ident: ref_50
  article-title: A three-patways psychological model of craving for alcohol
  publication-title: Alcohol Alcoholism
  doi: 10.1093/alcalc/34.2.197
– volume: 428
  start-page: 315
  year: 2001
  ident: ref_13
  article-title: Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid
  publication-title: Eur. J. Pharmacol
  doi: 10.1016/S0014-2999(01)01334-6
– volume: 27
  start-page: 418
  year: 2007
  ident: ref_46
  article-title: Use of alcohol during the treatment of alcohol dependence with gamma-Hydroxybutyric Acid: Risk of severe events are avoided by the dose fractioning of the drug
  publication-title: J. Clin. Psychopharmacol
  doi: 10.1097/01.jcp.0000280314.04237.a7
– volume: 61
  start-page: 176
  year: 2007
  ident: ref_61
  article-title: Differential regional effects of methadone maintenance compared to heroin dependence on mu-opioid receptor desensitization in rat brain
  publication-title: Synapse
  doi: 10.1002/syn.20355
– volume: 18
  start-page: 1
  year: 2009
  ident: ref_70
  article-title: The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data
  publication-title: Expert. Opin. Investig. Drug
  doi: 10.1517/13543780902905855
– volume: 365
  start-page: 2137
  year: 2005
  ident: ref_67
  article-title: Recognition and management of complications of new recreational drug use
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66737-2
– volume: 366
  start-page: 981
  year: 2005
  ident: ref_69
  article-title: Gamma-hydroxybutyrate as a treatment for alcoholism
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67371-0
– volume: 70
  start-page: 85
  year: 2003
  ident: ref_44
  article-title: Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study
  publication-title: Drug Alcohol Depend
  doi: 10.1016/S0376-8716(02)00340-X
– volume: 21
  start-page: 9
  year: 2007
  ident: ref_64
  article-title: Preclinical and clinical pharmacology of alcohol dependence
  publication-title: Fundam. Clin. Pharmacol
  doi: 10.1111/j.1472-8206.2006.00459.x
– volume: 33
  start-page: 465
  year: 1998
  ident: ref_35
  article-title: Gamma-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism
  publication-title: Alcohol Alcoholism
  doi: 10.1093/alcalc/33.5.465
– volume: 33
  start-page: 2587
  year: 1984
  ident: ref_6
  article-title: Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes
  publication-title: Biochem. Pharmacol
  doi: 10.1016/0006-2952(84)90629-4
– volume: 28
  start-page: 160
  year: 2007
  ident: ref_62
  article-title: PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users
  publication-title: Eur. J. Pharmacol
– volume: 46
  start-page: 187
  year: 2008
  ident: ref_68
  article-title: High mortality rates among GHB abusers in Western Sweden
  publication-title: Clin. Toxicol
  doi: 10.1080/15563650701263633
– volume: 3
  start-page: 83
  year: 2003
  ident: ref_34
  article-title: Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital
  publication-title: Acta. Med. Austriaca
– volume: 200
  start-page: 1207
  year: 1963
  ident: ref_3
  article-title: Gamma-hydroxybutyric, a normal brain metabolite
  publication-title: Nature
  doi: 10.1038/2001207a0
– volume: 20
  start-page: 217
  year: 2000
  ident: ref_53
  article-title: Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction
  publication-title: Alcohol
  doi: 10.1016/S0741-8329(99)00084-1
– ident: ref_54
  doi: 10.1177/0269881108094620
– volume: 90
  start-page: 839
  year: 2004
  ident: ref_60
  article-title: Effects of repeated cocaine on medial prefrontal cortical GABAB receptor modulation of neurotransmission in the mesocorticolimbic dopamine system
  publication-title: J. Neurochem
  doi: 10.1111/j.1471-4159.2004.02525.x
– volume: 23
  start-page: 3498
  year: 2003
  ident: ref_59
  article-title: GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine
  publication-title: J. Neurosci
  doi: 10.1523/JNEUROSCI.23-08-03498.2003
– volume: 77
  start-page: 209
  year: 2005
  ident: ref_65
  article-title: Gamma hydroxybutyric acid (GHB) withdrawal does not occur at therapeutic dosage
  publication-title: Drug. Alcohol. Depend
  doi: 10.1016/j.drugalcdep.2004.09.003
SSID ssj0038469
Score 2.1282763
SecondaryResourceType review_article
Snippet Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter γ-aminobutyric acid. Clinical trials have...
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter gamma-aminobutyric acid. Clinical trials...
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid structurally similar to the inhibitory neurotransmitter I3-aminobutyric acid. Clinical trials have...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1917
SubjectTerms Addictions
Alcohol use
Alcoholism - drug therapy
Fatty acids
Humans
Hydroxybutyrates - therapeutic use
Motivation
Randomized Controlled Trials as Topic
Review
Substance Withdrawal Syndrome - drug therapy
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dSxtBEB80vggiWr-itt0HKQou5m73voQiSauGgkFFwbdjv46mmEvU5MH_3pnsXdq02Jd7ueHY29md-c3O7G8ADrTTKgpsyEMlLJfSZlyhV-ZZYU2IiNwF07tVV724ey9_PEQPC3BV34WhssraJk4NtR0aOiM_CdHPxuQNz0ZPnJpGUXK17qChqs4K9uuUYWwRltAiR60GLHXOe9e3tWkW6GwJDwfolDi6xsSTbgqM-0_6vxz-GMJ5CmDmndQ_yPPvAso_PNLFGqxWUJK1ve7XYcGVH2DFn8Mxf71oA24u1WCgWPfVUr2Knoxf0fCxtulbdnjZ7RwxBK0MQSC7qyvO2bBgbd84l32vWuQad8razOcRNuH-4vzuW5dXbRS4kVKMuTZOyFQVJtUat2wii0AWiXRGpJFGNEIMfiqxyhklYkUFfSKxIjZOxaogIs8taJTD0u0AC1VMjF5ECCRlJm1qQm2NzPDpBNrcJhzX85abimOcWl085hhr0DTnc9PchC8z8ZEn13hPcK9WQl7tsZd8tiKa8Hn2FjcHZTxU6YYTFEEbmuJo35eIEykx4gqasO1V-nsgGRozGePXkzllzwSImHv-Tdn_OSXoDpMWwtpo97-j3oNln5miE519aIyfJ-4jApyx_lQt2zduDfuU
  priority: 102
  providerName: ProQuest
Title Gamma Hydroxybutyric Acid (GHB) for the Treatment of Alcohol Dependence: A Review
URI https://www.ncbi.nlm.nih.gov/pubmed/19578468
https://www.proquest.com/docview/227361028
https://www.proquest.com/docview/20888100
https://www.proquest.com/docview/67447681
https://pubmed.ncbi.nlm.nih.gov/PMC2705225
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3faxNBEB5s-yKIqFUbq3EfpCh4tnc72b0riNjSJBRaVAzk7dhfR1Pai9YEzH_fmWxyNdbiy77c3N0yuzvzze7sNwBvbLCmk_osyYz0CaIvEkNeOSkq7zJC5CGd3606OVX9AR4PO8MbSqGFAn_9M7TjelKDq4sPv3_OPtGC_8gRJ4Xsu6PzQH0iJM6xxxpszI-KOIsPmwMFSW6WkXCq1F6CFIREus3br6-6p1uY8-_UyT98UfcRPFyASPE5jvpjuBfqJ_Ag7sCJeLFoE772zOWlEWczz5kqdjqZkckTxo28eNvrH7wTBFcFwT_R5JqLcSVMLJkrlsVxXdgXRsQLLk9h0D36fthPFgUUEocoJ4l1QWJuKpdbS4tVY5VipTE4mXcs4RDm7jPam-CMVIZT-aT2UrlglKmYwvMZrNfjOmyByIxiLi-mAkIs0Ocus95hQW2QZG1b8H6pt9It2MW5yMVFSVEGq7lcUXMLdhrxH5FW4y7B7eUglMvJUWaEuRQjoxa8bp7SsuCzDlOH8ZREyHrm1Nu7JZRGpFgrbcHzOKQ3HSnIjKGir-uVwW4EmJJ79Uk9OptTc2d6jwBt58V__7oN9-O5FO_nvIT1ydU0vCJ4M7FtWNNDTW1-mHLb7bVh4-Do9Mu39nxKXwPEIf94
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6V9ABShXg3tFAfAIGE1a7t7AOpQil9bGkbAUql3ha_Vk1FN6VNhPLj-G_MxLuBgMqtl73syLLG9nwz9sw3AC-MN7oTOcGFlo4r5TKuEZV5Vjor0CP30bS26qgX58fq40nnZAF-NrUwlFbZ2MSpoXZDS3fk6wJxNiY0fH_xnVPTKHpcbTpo6LqzgtucMozVdR0HfvIDI7irzf1tXO6XQuzu9D_kvG4ywK1ScsSN9VKlurSpMbihE1VGqkyUtzLtGMRq4rfTidPeahlrSneTiZOx9TrWJdFc4ri3YFHR_UkLFrd2ep--NFAgEdzJ_44QBDlCcRJIPqXMNtYHZx4VieEDBUzzoPiPp_t3wuYfCLh7D-7Wrivrhr12HxZ89QCWwr0fC-VMD-Hznj4_1yyfOMqPMePRBA0t69qBY6_38q03DJ1khk4n6zcZ7mxYsm5o1Mu265a81r9jXRbeLR7B8Y1o9DG0qmHll4EJHRODGBEQKZUpl1phnFUZfr1EG9-Gt43eCltzmlNrjW8Fxjak5mJOzW14NRO_CGQe1wmuNItQ1Gf6qpjtwDaszf7iYaQXFl354RhF0GanONvrJeJEKYzwojY8CUv6eyIZGk8V4-jJ3GLPBIgIfP5PNTidEoKLZAPd6M7T_856DW7n_aPD4nC_d7ACd8KrGN0mrUJrdDn2z9C5Gpnn9RZm8PWmT80vAno5JA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3daxNBEB9qCyKI-Flj1e6DioJLerub2zuhSGqaplZDlRb6du7XYcReqk2Q_In-V87k9qJR6ltf7uWGZZmdnd_M7uxvAJ7YYE0n8YILIz1XyufcICrzvPROYEQekvnbqvfDdHCs3p50TlbgZ_MWhsoqG584d9R-7OiMvC0QZ1NCw3YZqyIOe_3XZ984NZCii9amm4aJXRb89pxtLL7xOAizH5jNnW_v93DpnwrR3z16M-Cx4QB3SskJty5IlZnSZdaicWtVJqrUKjiZdSziNnHdGe1NcEamhkrfpPYydcGkpiTKSxz3CqxpBH3MA9d2doeHHxtYkAj0FIsnCIgcYVnXhJ9S5lvt0ZeASsVUgpKnZYD8J-r9u3jzDzTs34QbMYxl3drubsFKqG7D9foMkNVPm-7Ahz1zemrYYOapVsZOJzN0uqzrRp493xvsvGAYMDMMQNlRU-3OxiXr1k17WS-253XhFeuy-g7jLhxfikbvwWo1rsJ9YMKkxCZGZERK5cpnTljvVI7fINHft-Blo7fCRX5zarPxtcA8h9RcLKm5Bc8W4mc1scdFghvNIhRxf58XC2tswebiL25Mum0xVRhPUQT9d4azvVgi1Uphtpe0YL1e0t8TydGRqhRH10uLvRAgUvDlP9Xo85wcXOgtDKk7D_476024iruneLc_PNiAa_UFGR0sPYTVyfdpeIRx1sQ-jhbM4NNlb5pfmr89aA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gamma+hydroxybutyric+acid+%28GHB%29+for+the+treatment+of+alcohol+dependence%3A+a+review&rft.jtitle=International+journal+of+environmental+research+and+public+health&rft.au=Caputo%2C+Fabio&rft.au=Vignoli%2C+Teo&rft.au=Maremmani%2C+Icro&rft.au=Bernardi%2C+Mauro&rft.date=2009-06-01&rft.issn=1660-4601&rft.eissn=1660-4601&rft.volume=6&rft.issue=6&rft.spage=1917&rft_id=info:doi/10.3390%2Fijerph6061917&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-4601&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-4601&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-4601&client=summon